WHO adds first maternal RSV vaccine to prequalification list
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants
Read Moreby Emily Kimber | Mar 24, 2025 | News | 0
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants
Read Moreby Chiani-Rae Garland | Oct 30, 2024 | News | 0
Approximately 8.2 million people were diagnosed with the infectious disease in 2023
Read Moreby Emily Kimber | Sep 16, 2024 | News | 0
The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex
Read Moreby John Pinching | Sep 13, 2022 | News | 0
Modelling indicates a 307% increase in cases identified between 2020 and 2021
Read Moreby John Pinching | Jun 23, 2022 | News | 0
Global surveillance systems show that recorded cases do not include any deaths
Read Moreby John Pinching | May 6, 2022 | News | 0
WHO have stated that Veklury recommendation is being updated following compelling new evidence of hospital reductions
Read Moreby Iona Everson | Dec 8, 2021 | News | 0
A senior official at the World Health Organisation (WHO) has said that Omicron is ‘highly unlikely’ to fully bypass vaccine protections.
Read Moreby Lucy Parsons | Jun 2, 2021 | News | 0
A WHO emergency use listing (EUL) is issued when a product meets international standards for safety, efficacy and manufacturing
Read Moreby Selina McKee | May 26, 2020 | News | 0
The Solidarity trial’s expert group will review all evidence available on the drug
Read Moreby Selina McKee | Apr 24, 2020 | News | 0
Gilead says the study was underpowered and so statistically meaningful conclusions could not be drawn
Read Moreby Selina McKee | Apr 16, 2020 | News | 0
Sir Andrew will take leave from his current role until the end of the year
Read Moreby Anna Smith | Feb 4, 2020 | News | 0
By last Tuesday, the death toll in China stood at more than 420, and the Chinese government had reported 20,438 confirmed cases.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479